| 货号 | KPTX227 |
|---|---|
| 品牌 | ProteoGenix |
| 样本类型 | Plasma, Serum |
| 检测范围 | 0.31-5 μg/mL |
| 保存溶液 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 实验类型 | Quantitative |
| 回收率 | 80-120% |
| 运输 | 2-8 ℃ |
| 规格 | Cinpanemab |
| 别名 | BIIB-054, CAS: 2094516-02-4 |
| 背景 | Cinpanemab is a human-derived monoclonal antibody directed against α-synuclein. Genetic and pathology evidence implicate this protein in the molecular pathogenesis of Parkinson's disease (PD) and other α-synucleinopathies such as dementia with Lewy bodies (DLB). In 2010, Biogen licensed cinpanemab from Neurimmune. The antibody was generated with reverse translational medicine technology from naturally occurring, presumably protective antibodies found in healthy aged donors, as were aducanumab and other antibodies in the Biogen-Neurimmune partnership. The antibody, previously known as BIIB054, binds to α-synuclein residues 1-10, with 800-fold higher affinity for aggregated over monomeric α-synuclein. The antibody inhibits α-synuclein spreading in cell-based assays, and slows pathology and motor symptoms in mice (Weihofen et al., 2019). |
| Note | For Research Use Only. |
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
